1. Home
  2. ENTO vs UPC Comparison

ENTO vs UPC Comparison

Compare ENTO & UPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • UPC
  • Stock Information
  • Founded
  • ENTO 2014
  • UPC 1998
  • Country
  • ENTO United States
  • UPC China
  • Employees
  • ENTO N/A
  • UPC N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • UPC Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTO Health Care
  • UPC Health Care
  • Exchange
  • ENTO Nasdaq
  • UPC Nasdaq
  • Market Cap
  • ENTO 2.3M
  • UPC 2.2M
  • IPO Year
  • ENTO 2016
  • UPC 2021
  • Fundamental
  • Price
  • ENTO $0.39
  • UPC $3.65
  • Analyst Decision
  • ENTO
  • UPC
  • Analyst Count
  • ENTO 0
  • UPC 0
  • Target Price
  • ENTO N/A
  • UPC N/A
  • AVG Volume (30 Days)
  • ENTO 852.3K
  • UPC 71.0K
  • Earning Date
  • ENTO 05-15-2025
  • UPC 07-07-2025
  • Dividend Yield
  • ENTO N/A
  • UPC N/A
  • EPS Growth
  • ENTO N/A
  • UPC N/A
  • EPS
  • ENTO N/A
  • UPC N/A
  • Revenue
  • ENTO N/A
  • UPC $23,024,458.00
  • Revenue This Year
  • ENTO N/A
  • UPC N/A
  • Revenue Next Year
  • ENTO N/A
  • UPC N/A
  • P/E Ratio
  • ENTO N/A
  • UPC N/A
  • Revenue Growth
  • ENTO N/A
  • UPC N/A
  • 52 Week Low
  • ENTO $0.19
  • UPC $2.51
  • 52 Week High
  • ENTO $1.54
  • UPC $2,592.00
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 44.28
  • UPC 41.11
  • Support Level
  • ENTO $0.45
  • UPC $3.45
  • Resistance Level
  • ENTO $0.57
  • UPC $4.10
  • Average True Range (ATR)
  • ENTO 0.07
  • UPC 0.23
  • MACD
  • ENTO -0.01
  • UPC -0.03
  • Stochastic Oscillator
  • ENTO 3.77
  • UPC 37.78

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About UPC Universe Pharmaceuticals Inc.

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Share on Social Networks: